glyco-engineered anti-CD20 monoclonal antibody CHO H01

{
  "id": "MLC-T-ONC-013983",
  "term": "glyco-engineered anti-CD20 monoclonal antibody CHO H01",
  "field": "Oncology and biomedicine",
  "definition": "A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/glyco-engineered-anti-cd20-monoclonal-antibody-cho-h01/"
}